NASDAQ · Healthcare
Invest in Burning Rock Biotech stock from India
Indian and foreign residents can buy Burning Rock Biotech (BNR) shares directly through Paasa.
By Paasa · Updated
Burning Rock Biotech at a glance
- Price
- $17.63-$1.31 (6.92%)
- Market cap
- $18.63M
- Day range
- $17.63 – $18.70
- P/E
- -1.84
- Dividend yield
- None
- Volume
- 13.76K
- 1 month
- +86.56%
- 6 months
- +9.30%
- YTD
- -12.51%
- 1 year
- +103.82%
- 5 years
- -89.62%
Burning Rock Biotech statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | CN¥539.6M | CN¥515.8M | CN¥537.4M | CN¥563.2M | CN¥507.9M |
| Gross profit | CN¥402.9M | CN¥362.4M | CN¥363.2M | CN¥380.0M | CN¥364.1M |
| Operating income | −CN¥54.8M | −CN¥357.6M | −CN¥669.3M | −CN¥980.4M | −CN¥797.1M |
| Net income | −CN¥55.3M | −CN¥346.6M | −CN¥653.7M | −CN¥971.2M | −CN¥796.7M |
| Earnings per share | −CN¥49.60 | −CN¥33.67 | −CN¥63.84 | −CN¥93.47 | −CN¥76.45 |
| EBITDA | −CN¥32.0M | −CN¥270.2M | −CN¥517.9M | −CN¥845.2M | −CN¥746.5M |
| Total assets | CN¥820.9M | CN¥885.3M | CN¥1.0B | CN¥1.6B | CN¥2.3B |
| Total debt | CN¥43.1M | CN¥52.3M | CN¥12.3M | CN¥50.8M | CN¥86.7M |
| Cash and short-term investments | CN¥481.4M | CN¥519.8M | CN¥615.1M | CN¥905.5M | CN¥1.5B |
| Shareholders' equity | CN¥535.6M | CN¥580.8M | CN¥768.4M | CN¥1.2B | CN¥1.8B |
| Operating cash flow | −CN¥28.4M | −CN¥92.3M | −CN¥255.8M | −CN¥456.8M | −CN¥477.9M |
| Free cash flow | −CN¥33.7M | −CN¥98.2M | −CN¥265.2M | −CN¥518.8M | −CN¥691.3M |
| Capital expenditure | −CN¥5.2M | −CN¥6.0M | −CN¥9.4M | −CN¥62.0M | −CN¥213.4M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in CNY; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| ProMIS Neurosciences | PMN | $10.85 | $97.30M |
| Ekso Bionics | EKSO | $15.90 | $38.57M |
| Aytu BioPharma | AYTU | $2.14 | $22.97M |
| American Shared Hospital Services | AMS | $1.42 | $9.41M |
| Advanced Biomed | ADVB | $6.23 | $8.61M |
| Co-Diagnostics | CODX | $1.07 | $6.69M |
| enVVeno Medical | NVNO | $7.80 | $5.42M |
| Aethlon Medical | AEMD | $6.52 | $3.43M |
Peers as grouped by the data provider. This is not an investment recommendation.
Analyst price targets
- Low
- —
- High
- —
- Median
- —
- Consensus
- —
Ratings: 3 buy · 0 hold · 0 sell. Consensus: Buy.
Published sell-side 12-month targets in USD, aggregated by the data provider. They are not Paasa's view and not a forecast.
How to invest in Burning Rock Biotech from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit.
Step 3
Search BNR and buy
Find Burning Rock Biotech by name or by its ticker, BNR, and place your order. Fractional shares are available and there is no minimum trade size, so you can buy by amount instead of whole shares.
Why invest in Burning Rock Biotech from India
What Burning Rock Biotech does
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. Burning Rock Biotech operates in the Medical - Diagnostics & Research industry within the Healthcare sector.
Hold a dollar asset
Burning Rock Biotech shares are priced in US dollars, so a weaker rupee adds to what they're worth in rupees. The rupee depreciated over 85% against the dollar between 2010 and 2025.
Buy a fraction of a share
Buy by amount, not by share, and get the matching fraction of one Burning Rock Biotech share. There is no minimum trade size.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Burning Rock Biotech stock from India?
Yes. Indian residents and NRIs can buy Burning Rock Biotech (BNR) shares directly through Paasa. Burning Rock Biotech is listed on NASDAQ, in the Medical - Diagnostics & Research industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full Burning Rock Biotech share?
No. You can buy part of one Burning Rock Biotech share and add to your position over time. One share is $17.63, and you can buy whole shares or any fraction; there is no minimum trade size.
How are Burning Rock Biotech dividends taxed for Indian investors?
Burning Rock Biotech trades on NASDAQ but is domiciled in China, so any withholding on its dividends follows that country's rules rather than those of the US. What trades there is a depositary receipt over Burning Rock Biotech shares rather than the ordinary share itself. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell Burning Rock Biotech shares?
The US does not levy capital gains tax on shares for Indian residents. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the USD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.